These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

174 related items for PubMed ID: 10531373

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Cisplatin-induced response of c-jun N-terminal kinase 1 and extracellular signal--regulated protein kinases 1 and 2 in a series of cisplatin-resistant ovarian carcinoma cell lines.
    Cui W, Yazlovitskaya EM, Mayo MS, Pelling JC, Persons DL.
    Mol Carcinog; 2000 Dec; 29(4):219-28. PubMed ID: 11170260
    [Abstract] [Full Text] [Related]

  • 4. Role of mitogen-activated protein kinase/extracellular signal-regulated kinase cascade in gonadotropin-releasing hormone-induced growth inhibition of a human ovarian cancer cell line.
    Kimura A, Ohmichi M, Kurachi H, Ikegami H, Hayakawa J, Tasaka K, Kanda Y, Nishio Y, Jikihara H, Matsuura N, Murata Y.
    Cancer Res; 1999 Oct 15; 59(20):5133-42. PubMed ID: 10537288
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Tamoxifen inhibits cell proliferation via mitogen-activated protein kinase cascades in human ovarian cancer cell lines in a manner not dependent on the expression of estrogen receptor or the sensitivity to cisplatin.
    Mabuchi S, Ohmichi M, Kimura A, Ikebuchi Y, Hisamoto K, Arimoto-Ishida E, Nishio Y, Takahashi K, Tasaka K, Murata Y.
    Endocrinology; 2004 Mar 15; 145(3):1302-13. PubMed ID: 14645110
    [Abstract] [Full Text] [Related]

  • 7. Activation of the luteinizing hormone beta promoter by gonadotropin-releasing hormone requires c-Jun NH2-terminal protein kinase.
    Yokoi T, Ohmichi M, Tasaka K, Kimura A, Kanda Y, Hayakawa J, Tahara M, Hisamoto K, Kurachi H, Murata Y.
    J Biol Chem; 2000 Jul 14; 275(28):21639-47. PubMed ID: 10787426
    [Abstract] [Full Text] [Related]

  • 8. Sustained activation of JNK/p38 MAPK pathways in response to cisplatin leads to Fas ligand induction and cell death in ovarian carcinoma cells.
    Mansouri A, Ridgway LD, Korapati AL, Zhang Q, Tian L, Wang Y, Siddik ZH, Mills GB, Claret FX.
    J Biol Chem; 2003 May 23; 278(21):19245-56. PubMed ID: 12637505
    [Abstract] [Full Text] [Related]

  • 9. Roles of JNK, p38 and ERK mitogen-activated protein kinases in the growth inhibition and apoptosis induced by cadmium.
    Chuang SM, Wang IC, Yang JL.
    Carcinogenesis; 2000 Jul 23; 21(7):1423-32. PubMed ID: 10874022
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Inhibition of extracellular signal-regulated kinase (ERK) mediates cell cycle phase independent apoptosis in vinblastine-treated ML-1 cells.
    Stadheim TA, Xiao H, Eastman A.
    Cancer Res; 2001 Feb 15; 61(4):1533-40. PubMed ID: 11245462
    [Abstract] [Full Text] [Related]

  • 12. The Jun kinase/stress-activated protein kinase pathway functions to regulate DNA repair and inhibition of the pathway sensitizes tumor cells to cisplatin.
    Potapova O, Haghighi A, Bost F, Liu C, Birrer MJ, Gjerset R, Mercola D.
    J Biol Chem; 1997 May 30; 272(22):14041-4. PubMed ID: 9162025
    [Abstract] [Full Text] [Related]

  • 13. Extracellular signal-regulated kinase, Jun N-terminal kinase, p38, and c-Src are involved in gonadotropin-releasing hormone-stimulated activity of the glycoprotein hormone follicle-stimulating hormone beta-subunit promoter.
    Bonfil D, Chuderland D, Kraus S, Shahbazian D, Friedberg I, Seger R, Naor Z.
    Endocrinology; 2004 May 30; 145(5):2228-44. PubMed ID: 14736735
    [Abstract] [Full Text] [Related]

  • 14. Reversing chemoresistance in cisplatin-resistant human ovarian cancer cells: a role of c-Jun NH2-terminal kinase 1.
    Li F, Meng L, Zhou J, Xing H, Wang S, Xu G, Zhu H, Wang B, Chen G, Lu YP, Ma D.
    Biochem Biophys Res Commun; 2005 Oct 07; 335(4):1070-7. PubMed ID: 16105650
    [Abstract] [Full Text] [Related]

  • 15. Signal transduction in fibroblasts stably transformed by [Val12]Ras--the activities of extracellular-signal-regulated kinase and Jun N-terminal kinase are only moderately increased, and the activity of the delta-inhibitor of c-Jun is not alleviated.
    Ljungdahl S, Linder S, Sollerbrant K, Svensson C, Shoshan MC.
    Eur J Biochem; 1997 Nov 01; 249(3):648-56. PubMed ID: 9395309
    [Abstract] [Full Text] [Related]

  • 16. Anti-apoptotic effect of quercetin: intervention in the JNK- and ERK-mediated apoptotic pathways.
    Ishikawa Y, Kitamura M.
    Kidney Int; 2000 Sep 01; 58(3):1078-87. PubMed ID: 10972672
    [Abstract] [Full Text] [Related]

  • 17. alpha-TEA inhibits survival and enhances death pathways in cisplatin sensitive and resistant human ovarian cancer cells.
    Yu W, Shun MC, Anderson K, Chen H, Sanders BG, Kline K.
    Apoptosis; 2006 Oct 01; 11(10):1813-23. PubMed ID: 16850165
    [Abstract] [Full Text] [Related]

  • 18. Lack of c-Jun activity increases survival to cisplatin.
    Sánchez-Pérez I, Perona R.
    FEBS Lett; 1999 Jun 18; 453(1-2):151-8. PubMed ID: 10403393
    [Abstract] [Full Text] [Related]

  • 19. Activated Ki-Ras suppresses 12-O-tetradecanoylphorbol-13-acetate-induced activation of the c-Jun NH2-terminal kinase pathway in human colon cancer cells.
    Okumura K, Shirasawa S, Nishioka M, Sasazuki T.
    Cancer Res; 1999 May 15; 59(10):2445-50. PubMed ID: 10344756
    [Abstract] [Full Text] [Related]

  • 20. Prolactin-releasing peptide activation of the prolactin promoter is differentially mediated by extracellular signal-regulated protein kinase and c-Jun N-terminal protein kinase.
    Kimura A, Ohmichi M, Tasaka K, Kanda Y, Ikegami H, Hayakawa J, Hisamoto K, Morishige K, Hinuma S, Kurachi H, Murata Y.
    J Biol Chem; 2000 Feb 04; 275(5):3667-74. PubMed ID: 10652364
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.